- Home
- USAU vs MCRB Comparison
USAU vs MCRB Comparison
Compare USAU & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAU
- MCRB
- Stock Information
- Founded
- USAU 2014
- MCRB 2010
- Country
- USAU United States
- MCRB United States
- Employees
- USAU N/A
- MCRB N/A
- Industry
- USAU Precious Metals
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- USAU Basic Materials
- MCRB Health Care
- Exchange
- USAU Nasdaq
- MCRB Nasdaq
- Market Cap
- USAU 126.8M
- MCRB 125.7M
- IPO Year
- USAU N/A
- MCRB 2015
- Fundamental
- Price
- USAU $11.34
- MCRB $16.69
- Analyst Decision
- USAU Strong Buy
- MCRB Hold
- Analyst Count
- USAU 2
- MCRB 4
- Target Price
- USAU $17.00
- MCRB $73.67
- AVG Volume (30 Days)
- USAU 237.1K
- MCRB 133.0K
- Earning Date
- USAU 09-15-2025
- MCRB 08-06-2025
- Dividend Yield
- USAU N/A
- MCRB N/A
- EPS Growth
- USAU N/A
- MCRB N/A
- EPS
- USAU N/A
- MCRB 10.22
- Revenue
- USAU N/A
- MCRB N/A
- Revenue This Year
- USAU N/A
- MCRB N/A
- Revenue Next Year
- USAU N/A
- MCRB N/A
- P/E Ratio
- USAU N/A
- MCRB $1.70
- Revenue Growth
- USAU N/A
- MCRB N/A
- 52 Week Low
- USAU $4.86
- MCRB $6.53
- 52 Week High
- USAU $14.39
- MCRB $26.40
- Technical
- Relative Strength Index (RSI)
- USAU 46.34
- MCRB 64.72
- Support Level
- USAU $11.80
- MCRB $14.06
- Resistance Level
- USAU $12.66
- MCRB $17.52
- Average True Range (ATR)
- USAU 0.55
- MCRB 1.38
- MACD
- USAU 0.08
- MCRB 0.13
- Stochastic Oscillator
- USAU 48.64
- MCRB 84.54
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.